# DEA Updates Synthetic Cannabinoid Regulation: Schedule I Placement of CUMYL-PEGACLONE > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/dea-synthetic-cannabinoid-regulation-update-schedule-i-placement/ > **Published:** 2026-06-19T23:47:01-04:00 | **Last Modified / Clinically Audited:** 2026-09-29T00:25:31-04:00 > **Clinical Summary:** Explore the DEA synthetic cannabinoid regulation update placing CUMYL-PEGACLONE in Schedule I under the Controlled Substances Act in 2026. --- ✦ New CED Clinical Relevance #70 Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. ⚒ Policy Watch  |  Federal Register cannabis_policyfederal_lawDEA_schedulingcontrolled_substancesCUMYL-PEGACLONESchedule_Istate_regulation Clinical Summary The DEA has placed CUMYL-PEGACLONE, a synthetic cannabinoid analog, into Schedule I of the [Controlled Substances](https://cedclinic.com/dea-scheduling-cannabis-policy-march-15-2026/) Act, designating it as having no accepted medical use and high abuse potential. This regulatory action reflects ongoing efforts to control novel psychoactive substances that emerge to circumvent existing cannabis restrictions, particularly synthetic cannabinoids marketed as “legal highs” or K2/spice products. Clinicians should be aware that patients presenting with acute psychiatric symptoms, seizures, or severe anxiety may have been exposed to these unregulated synthetic compounds, which often produce more severe toxicity than natural cannabis. The scheduling of CUMYL-PEGACLONE does not affect the clinical use of approved cannabinoid medications or legitimate [cannabis therapy](https://cedclinic.com/cannabis-based-therapies-smoking-cessation/) where permitted by state law, but it signals the regulatory landscape’s response to illicit synthetic alternatives. Healthcare providers should maintain vigilance for patients reporting use of branded synthetic cannabinoid products and educate patients about the unpredictable and potentially dangerous effects of these substances. Clinicians prescribing or recommending cannabis should counsel patients on obtaining products only from regulated, legal sources to avoid accidental exposure to dangerous synthetic analogs. Clinical Perspective 🔬 The scheduling of CUMYL-PEGACLONE as a Schedule I controlled substance reflects ongoing regulatory efforts to manage novel synthetic cannabinoids before they establish significant market presence and [public health](https://cedclinic.com/cannabis-mold-contamination-risks-recall-safety/) burden. This synthetic cannabinoid, like many designer drugs, likely poses potency and safety concerns distinct from plant-derived cannabis, though [clinical data](https://cedclinic.com/uk-germany-medical-cannabis-markets-double-2025/) on its specific toxicity profile remain limited at this early stage. Clinicians should be aware that rapid scheduling decisions sometimes outpace formal pharmacological characterization, creating knowledge gaps about the actual clinical harms these substances cause compared to other cannabinoid products patients may encounter. The regulatory approach nonetheless has practical value: it prevents legal commercialization and may reduce emergency department presentations associated with unpredictable synthetic cannabinoid toxidromes. Healthcare providers should remain alert to patients presenting with acute psychiatric, cardiovascular, or neurological symptoms who report using “research chemicals” or designer cannabinoids, recognize that routine cannabis 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/forum/ask-dr-caplan/) Have thoughts on this? Share it: [𝕏 Share on X](https://twitter.com/intent/tweet?text=Just+read+this+on+CEDclinic.com%3A+Schedules+of+Controlled+Substances%3A+Placement+of+CUMYL-PEGACLONE+in+Schedule+I+%40drcaplan&url=https%3A%2F%2Fwww.federalregister.gov%2Fdocuments%2F2026%2F05%2F13%2F2026-09566%2Fschedules-of-controlled-substances-placement-of-cumyl-pegaclone-in-schedule-i)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fwww.federalregister.gov%2Fdocuments%2F2026%2F05%2F13%2F2026-09566%2Fschedules-of-controlled-substances-placement-of-cumyl-pegaclone-in-schedule-i)[🦅 Share on BlueSky](https://bsky.app/intent/compose?text=Just+read+this%3A+Schedules+of+Controlled+Substances%3A+Placement+of+CUMYL-PEGACLONE+in+Schedule+I+--+via+%40drcaplan.bsky.social+https%3A%2F%2Fwww.federalregister.gov%2Fdocuments%2F2026%2F05%2F13%2F2026-09566%2Fschedules-of-controlled-substances-placement-of-cumyl-pegaclone-in-schedule-i)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan)[📝 Read more on Substack](https://doctorapprovedcannabis.substack.com/)[🔔 Subscribe via RSS](https://cedclinic.com/feed/) Further Reading CED Clinic Blog[Why Cannabis Works](https://cedclinic.com/why-cannabis-works/) Evidence Watch[Cannabis and Heart Health](https://cedclinic.com/cannabis-cardiovascular-health-study/) CED Clinic Blog[Cannabis for Sleep](https://cedclinic.com/cannabis-for-sleep/) Related Articles - Schedules of [Controlled Substances](https://cedclinic.com/dea-scheduling-cannabis-policy-march-15-2026/): Temporary Placement of 2-Fluorodeschloroketamine in Schedule I - [Schedules of Controlled Substances: Placement of Diphenidine in Schedule I](https://cedclinic.com/diphenidine-schedule-i-dea-update-controlled-substance-placement/) - [Policy Watch: 20 Regulatory Updates — June 19, 2026](https://cedclinic.com/dea-schedule-i-synthetic-cannabinoids-control-update-june-2026/) 📰 Source: [https://www.federalregister.gov/documents/2026/05/13/2026-09566/schedules-of-controlled-substances-placement-of-cumyl-pegaclone-in-schedule-i](https://www.federalregister.gov/documents/2026/05/13/2026-09566/schedules-of-controlled-substances-placement-of-cumyl-pegaclone-in-schedule-i) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) RELATED READING AT CED CLINIC Continue exploring the evidence [DEA Places Synthetic Cannabinoid CUMYL-PEGACLONE in Schedule I](https://cedclinic.com/cumyl-pegaclone-schedule-i-placement-dea-synthetic-cannabinoid/) Detailed analysis of DEA’s placement of CUMYL-PEGACLONE in Schedule I, highlighting regulatory and clinical perspectives. [Read More](https://cedclinic.com/cumyl-pegaclone-schedule-i-placement-dea-synthetic-cannabinoid/) [Schedules of Controlled Substances: Placement of Diphenidine in Schedule I](https://cedclinic.com/diphenidine-schedule-i-controlled-substance-update/) Explore the [federal scheduling](https://cedclinic.com/investigator-initiated-cannabis-research-barriers/) of Diphenidine and its implications for synthetic drug regulation. [Explore Article](https://cedclinic.com/diphenidine-schedule-i-controlled-substance-update/) [Schedules of Controlled Substances: Temporary Placement of 2-Fluorodeschloroketamine in Schedule I](https://cedclinic.com/dea-synthetic-ketamine-analog-control-2-fdck-schedule-i/) Review the temporary scheduling of 2-Fluorodeschloroketamine and its regulatory context. [Learn More](https://cedclinic.com/dea-synthetic-ketamine-analog-control-2-fdck-schedule-i/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Former CMO Canna Care Docs (250,000+ patients supervised), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).